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Background: The population of elderly people is increasing and so is the population of breast cancer patients
aged ≥80 years. The aim of our retrospective study was to identify independent prognostic factors for the duration
of breast cancer-specific survival of surgically treated patients aged ≥80 years. The secondary aim was to determine
the appropriate surgical treatment of breast cancer in patients aged ≥80 years.
Methods: We reviewed the medical records of 154 patients aged ≥80 years with early-stage breast cancer (mean
age 83 years) who underwent surgery at the tertiary cancer center in the period from 2000 to 2008. Tumor stage
was pT1/pT2 and pT3/pT4 in 75% and 25%, respectively. Surgical treatment comprised: quadrantectomy (in 27%),
mastectomy (in 73%), axillary dissection (in 57%), and sentinel lymph node biopsy (in 18%), while 25% of patients
had no axillary surgery.
Results: During a median follow-up of 5.3 years, 31% of patients died of breast cancer, while 28% of patients died
of other causes. Half of our patients with poorly differentiated breast cancer or estrogen receptor-negative tumor
died of breast cancer. Multivariate statistical analysis showed that the pathological T-stage, pathological N-stage
and estrogen receptors were independent prognostic factors for the duration of breast cancer-specific survival
of patients.
Conclusion: Short breast cancer-specific survival indicates that, in patients aged ≥80 years, breast cancer with
metastases in axillary lymph nodes can be an aggressive disease.
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The population of elderly people is increasing [1], and so
is the number of elderly breast cancer patients. Accord-
ing to the data of the Slovenian Cancer Registry for
2008, 11% of all breast cancer patients were aged more
than 80 years [2]. According to the data of the Statistical
Office of the Republic of Slovenia, life expectancy in
2010 was 9.02 years for women aged between 80 and
84 years and 6.26 years for women aged 85 years or
older [3]. Unfortunately, there is no consensus or guide-
lines on how to treat elderly breast cancer patients [4].
The aim of our retrospective study was to identify in-
dependent prognostic factors for the duration of breast
cancer-specific survival of surgically treated patients
aged ≥80 years. The secondary aim was to determine the* Correspondence: nbesic@onko-i.si
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unless otherwise stated.appropriate surgical treatment of breast cancer in patients
aged ≥80 years.Methods
This study included 154 patients who underwent surgery
in the period from 2000 to 2008, when they were aged
80 years or older. Their medical records were reviewed.
Data on the extent of the disease, pathomorphology of
the tumor, treatment method, extent of breast and axil-
lary lymph node surgery, complications after the surgery,
disease recurrence, cause of death, length of survival,
and length of breast cancer-specific survival were col-
lected. The cause of death was determined from the data
collected from death certificates. Postoperative compli-
cations were those observed within three months of the
surgical procedure.
In the period from 2000 to 2008, a total of 469 pa-
tients aged 80 years or older were treated at the Instituted. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Besic et al. BMC Cancer 2014, 14:700 Page 2 of 7
http://www.biomedcentral.com/1471-2407/14/700of Oncology Ljubljana (IOL). As many as 437 (93%) of
these received their first treatment at the IOL. Patients
were not randomly selected for surgical therapy. In the
majority of cases, a surgical procedure was proposed but
declined by the patients or their relatives, therefore the
majority of them were treated by hormonal therapy only.
Altogether, 403 patients had locally or locoregionally
limited disease. Before treatment, distant metastases
were found in 34 patients.
Disease stage was determined according to the 7th edi-
tion of the TNM classification from 2010 [5]. Stage of
the disease was unknown in 38 patients who did not
have lymph node surgery and were clinically without
suspicious or metastatic lymph nodes. Prior to the surgi-
cal procedure, all patients underwent chest X-ray. Skel-
etal scintigraphy was performed in 60 patients, and 21
patients had an ultrasound examination of the abdomen.
Considering their physical condition, the patients were
grouped into four categories according to the classifica-
tion of the American Society of Anesthesiologists [6].
Patients were further divided according to whether or
not they received surgical treatment in line with the
guidelines established at the IOL [7]. With regard to
lymph node surgery, the patients were categorized into
three groups: no lymph node surgery, sentinel lymph
node biopsy only, and lymphadenectomy. When more
than the sentinel lymph node was required, the standard
practice was formal levels 1 and 2 axillary lymph node dis-
section. In patients with evident metastases in level 3 of
the axilla, all three levels of lymph nodes were dissected.
Generally, the guidelines for breast cancer therapy
established at the IOL followed the current consensus
statements of the St. Gallen and the European Society
of Surgical Oncology, the European Society of Medical
Oncology, as well as the European Society of Radiother-
apy and Oncology. Of course, these guidelines were
regularly updated during treatment of our patients. Ac-
cording to the institutional guidelines for postoperative
radiotherapy, all patients aged 70 years or less under-
went whole-breast external beam radiotherapy in case of
breast conserving surgery, with at least a 2-mm tumor-
free surgical margin. Furthermore, all patients with a
tumor larger than 5 cm after mastectomy, tumors with-
out a clear surgical margin and/or with more than 3
metastatic lymph nodes had external beam radiotherapy
of the thoracic region and regional lymph nodes. However,
according to the institutional guidelines, radiotherapy
could be avoided in patients older than 70 years in case of
a large surgical margin, a tumor smaller than 2 cm, and
in case of a low or moderate tumor grade which was
hormone-dependent. However, in patients aged ≥80 years,
postoperative radiation therapy was often omitted also in
other circumstances, especially if the patient was not willing
to undergo radiotherapy.Our study was reviewed and approved by the Institu-
tional Review Board of the Institute of Oncology Ljubljana
and was performed in accordance with the ethical stan-
dards laid down in an appropriate version of the 1964
Declaration of Helsinki. Our study was conducted with
the understanding and consent of the subjects. During the
first admission to our Institute or during a follow-up visit,
all of our patients are asked to give consent for the use of
their chart and/or bioptic material for scientific purposes.
Since the Institutional Review Board of the Institute
of Oncology Ljubljana approved this specific study, our
patients were not asked to give written consent for this
specific study.
Univariate analysis was used to identify factors associ-
ated with disease-free and disease-specific survival.
Disease-specific survival and disease-free interval were
compared by a log-rank test. All comparisons were two-
sided, and a p-value of <0.05 was considered statistically
significant. Survival curves were calculated according to
the Kaplan–Meier method. Cox’s multivariate regression
model was used to identify independent prognostic fac-
tors of disease-free and disease-specific survival. The
univariate and multivariate statistical analyses of the
length of survival in breast cancer patients were per-
formed using the SPSS 16.0 software for Windows
(SPSS; Chicago, IL).
Results
The data on patients and treatment methods are presented
in Table 1. The patients were aged 80–90 years (mean age
83 years). Breast carcinoma was detected by clinical exam-
ination and imaging in 82% and 18%, respectively. There
was no difference between the means of detection in older
versus younger age groups (p = 0.54).
Neoadjuvant hormonal therapy was used in 13% of
patients. Breast-conserving surgery, mastectomy and
postoperative radiotherapy were done in 27%, 73% and
12% of patients, respectively. Axillary lymphadenectomy,
sentinel node biopsy and no axillary surgery were per-
formed in 57%, 18% and 25%, respectively. In our pa-
tients, the following deviation from the guidelines for
surgical treatment occurred in 53 cases: omission of the
sentinel lymph node procedure in 38 patients, omission
of lymphadenectomy in 11 patients with metastatic
lymph nodes (5 with clinically evident metastatic lymph
nodes and 6 with positive sentinel lymph nodes), and
omission of reoperation because of positive or close sur-
gical margins in 4 patients.
By means of pathomorphological examination, we were
able to determine that the cancer measured 5–150 mm in
diameter (arithmetic mean 37 mm, median 25 mm).
Tumor stage was pT1/pT2 and pT3/pT4 in 75% and 25%,
respectively. pN1/pN2/pN3 and pN0/unknown were re-
ported in 54% and 46% of patients. Among 71 patents
Table 1 Characteristics of patients and treatment and univariate analysis of breast cancer specific survival






(N = 106) (N = 48)
American Society of Anaesthesiology score 1 or 2 71 29 0.43
3 or 4 35 19
Eastern Cooperative Oncology Group performance status 1 or 2 94 40 0.36
3 or 4 12 8
Preoperative hormonal treatment Yes 11 9 0.15
No 95 39
pT-stage pT1 or pT2 86 29 0.006
pT3 or pT4 20 19
pN-stage pN0 or unknown 69 14 0.001
pN1 or pN2 or pN3 37 34
Breast cancer surgical procedure Quadrantectomy 32 10 0.23
Mastectomy 74 38
Axillary lymphadenectomy Yes 51 36 0.002
No 55 12
Lymph node surgery Without 31 7 0.003
Sentinel node biopsy 24 4
Lymphadenectomy 51 37
Tumor differentiation 1 or 2 71 19 0.003
3 35 29
Oestrogen receptors Negative 9 11 0.014
Positive 97 37
Progesterone receptors Negative 29 35 0.97
Positive 77 13
Molecular subtype Hormone positive 96 38 0.047
Triple negative 5 8
HER-2 positive 5 2
Surgery in accordance with guidelines Yes 47 8 0.001
No 59 40
Adjuvant systemic therapy Tamoxifen 44 9 -




Radiotherapy Yes 10 7 0.34
No 96 41
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18 and 13 cases, respectively. Stage I, stage II, stage III/IV,
and unknown stage of breast carcinoma were present in
17%, 36%, 35% and 12% of patients, respectively. With re-
gard to molecular subtype, the tumor was hormone-
positive, triple-negative and HER-2 positive in 87%, 8%
and 5%, respectively. There were no differences in surgical
therapy between the molecular subtypes of breast cancer.After the surgical procedure, the patients were followed
up from 0.1 to 13.1 years (median 5.3 years). During this
period, breast cancer recurred in 25% of patients. Five pa-
tients had local, regional and distant recurrence, twelve
distant and local recurrence, four patients developed dis-
tant and regional recurrence, sixteen patients only distant,
while two patients had only local recurrence. Five-year
breast cancer-specific survival was 83%. A total of 31% of
Figure 2 pN-stage and breast cancer specific survival. pN0 or
not known (bold line). pN1 or pN2 or pN3 (dashed line).
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died of other causes.
Postoperative complications were observed in 25 (16%)
of patients. Five (3%) of them suffered serious, life-
threatening complications. On the first day after the surgi-
cal procedure, one patient experienced a myocardial
infarction, which led to her death. Two patients suffered a
cerebrovascular insult, and one of them also developed
pulmonary embolism. During the surgical procedure, the
patient with the locoregionally advanced cancer developed
an iatrogenic pneumothorax. On the first day after the
procedure, one patient was found to be bleeding into the
wound and had to undergo another surgical procedure.
Five patients were re-hospitalized for late complications:
four of them had a wound infection and one came with an
obstructed drain tube.
The univariate analysis showed that the length of survival
of breast cancer patients correlated with the following fac-
tors: pathological T-stage (Figure 1), pathological N-stage
(Figure 2), axillary lymphadenectomy, lymph node surgery
(Figure 3), estrogen receptors (Figure 4), degree of tumor
differentiation, molecular subtype, and surgical treatment
according to the established guidelines (Table 1).
All of the above-mentioned factors were included in the
multivariate analysis (Table 2). Using the multivariate stat-
istical analysis, we found that the pathological T-stage,
pathological N-stage and estrogen receptors are independ-
ent prognostic factors for the duration of breast cancer-
specific survival of patients. Patients with T3 or T4 tumors
have a 1.04-times higher risk of shorter survival due to
cancer compared to patients with T1 or T2 tumors. Pa-
tients with regional metastases have a 4.6-times higher risk
of shorter survival due to cancer compared to patients
with no metastases. Patients without estrogen receptors inFigure 1 pT-stage and breast cancer specific survival. pT1 or
pT2 (bold line). pT3 or pT4 (dashed line).the tumor have a 3.9-times higher risk of shorter survival
due to cancer compared to patients with estrogen recep-
tors in the tumor.
Discussion
In our patients, the mean and median tumor size was
37 mm and 25 mm, respectively. Vetter et al. reported that
the patients aged 80 years or older had larger median
tumor size at diagnosis (25 mm vs. 18 mm) and higher
disease stages compared to younger patients [8]. In our
patients, breast carcinoma was detected by clinical exam-
ination and imaging in 82% and 18%, respectively. This isFigure 3 Axillary lymph node surgical procedure and breast
cancer specific survival. Without lymph node surgery (bold line).
Sentinel node biopsy only (dashed line). Lymphadenectomy
(dotted line).
Figure 4 Estrogen receptors and breast cancer specific survival.
Estrogen receptor positive tumor (bold line). Estrogen receptor
negative tumor (dashed line).
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tumors of older patients were more often detected by
clinical examination (39% vs. 17%) and less often by mam-
mography/sonography (10% vs. 30%) [8]. However, screen-
ing mammography in patients aged 80 years or more is
controversial [9-11].
There are no specific recommendations in the litera-
ture concerning the extent of surgical procedure per-
formed to the breast and axillary lymph nodes in breast
cancer patients aged 80 years or older [12]. The question
that arises is whether to remove the entire breast and
what to do with the axillary lymph nodes where no me-
tastases were detected [12]. Multivariate analysis of the
data on surgical treatment of our 154 patients showed
that the pathological T-stage, pathological N-stage and
estrogen receptors in the tumor were independent fac-
tors associated with the duration of breast cancer-
specific survival of patients. The multivariate analysisTable 2 Results of multivariate analysis of breast cancer
specific survival and independent factors for length of
survival (p < 0.0001; 3 degrees of freeedom; −2 log
likelihood = 396.46; chi-square = 44.78)
Characteristics Subgroup Relative Risk Confidence
Interval 95%
for Relative Risk
pT-stage pT1 or pT2 1
pT3 or pT4 1.045 1.017 – 1.074
pN-stage pN0 or unknown 1
pN1 or pN2 or pN3 4.589 2.393 – 8.799
Estrogen receptors Positive 1
Negative 3.935 1.940 – 7.984also included data on the extent of breast and axillary
lymph node surgery and data on the implementation of
surgical treatment in line with the established guidelines.
However, none of these factors were independent, which
favors the decision of surgeons to adjust the extent of
surgical treatment to the stage of the disease and the
general condition of the patient. At the IOL, mastectomy
was performed in 73% of cases. In the USA, mastectomy
was performed in less than 40% of patients aged 80 years
or older with stage I disease and in approximately 62%
of patients with stage II disease [13]. In the US, follow-
ing breast-conserving surgery in stage I and II of the dis-
ease, breast irradiation was performed in 31% of patients
with stage I cancer and in 15% of patients with stage II
cancer [13]. Due to a high proportion of patients who
underwent mastectomy, irradiation was performed only
in 12% of our patients.
There is a confounding variable that the increased use
of axillary surgery is likely a surrogate for more advance
disease. Most studies to date, however, have shown that
regional disease in the axilla portends a worse prognosis,
upon which surgical management of the axilla has no
impact. Prognosis of patients is determined by standard
of adjuvant care medical therapy. Considering lymph
node surgery, our data are similar to those from the
USA and the Netherlands. Lymph node surgery was per-
formed in the Netherlands, at the MD Anderson Cancer
Center, and at the IOL in 71% [14], 71% [12] and 75% of
breast cancer patients, respectively.
In elderly patients, the treatment method must be se-
lected also based on their life expectancy and concomi-
tant diseases threatening their health. Safety of the
surgical procedure or anesthesia can be assessed by the
surgeon or anesthesiologist using the physical status
classification of the American Society of Anesthesiolo-
gists (ASA) [6]. In patients with the ASA physical status
4, anesthesia is a very dangerous procedure, whereas it is
safe in patients with ASA physical status 1 or 2. After
the surgical procedure, five (3%) of our very old patients
experienced serious and life-threatening health compli-
cations. Three of these patients were categorized into
the ASA 2 group, and two of these three did not have a
history of high blood pressure or cardiovascular disease.
However, one of them developed a cerebrovascular in-
sult and pulmonary embolism, while the other suffered a
myocardial infarction on the first day after the surgery
and died of it later on. At the MD Anderson Cancer
Center, complications after the surgical treatment were
reported in 6% (11/188) of their patients aged more than
80 years, and one patient died after the surgical proced-
ure [15]. In order to better assess the risk associated
with anesthesia or surgery and the patient’s life expect-
ancy, the decision on the type of treatment should be
based on a geriatric assessment which includes data on
Besic et al. BMC Cancer 2014, 14:700 Page 6 of 7
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status of the patient as well as her social status and so-
cial activities, including the information on comorbidi-
ties and concomitant medications [16].
Many patients aged 80 years or older die because of
breast cancer. This was confirmed also by the present
study: 31% of patients died of breast cancer during the
median follow-up period of 5.3 years. In the United
Kingdom, mortality due to breast cancer in women aged
80 years or older was 39% in the period from 1999 to 2009
[17]. Data on the survival of patients in the USA show that
patients with early-stage breast cancer aged 80 years or
older are at a higher risk of dying due to breast cancer
than younger patients [13]. The higher morbidity is attrib-
uted to the fact that, compared to younger patients,
elderly patients are rarely treated with cytostatics or re-
ceive less effective treatment schedules with fewer adverse
events. However, the characteristics of tumors in elderly
patients are similar to those in post-menopausal patients
younger than 70 years [13]. Our results are consistent with
this finding, as half of patients with poorly differentiated
breast cancer or estrogen receptor-negative tumor died of
breast cancer. Therefore, elderly patients with an aggres-
sive tumor and/or locoregionally advanced breast cancer
should probably also be treated with cytostatics. Yet, only
one percent of our patients were treated with cytostatics.
In the USA, among patients with stage I or stage II breast
cancer with a hormone-negative tumor and positive lymph
nodes, treatment with cytostatics was administered to 38%
of patients aged 80–84 years and 10% of patients aged
85 years or older [13].
Hormonal treatment was preferred over surgery at the
IOL in the period from 2001 to 2004 [18]. A total of 61%
of 221 patients with early-stage breast cancer underwent
hormonal treatment alone [18]. By means of multivariate
analysis, we found that surgical treatment was an inde-
pendent prognostic factor for longer survival, increasing
the relative possibility of longer survival by 2.1 times [18].
The median overall survival was 83 months for patients
treated with surgery, 57 months for patients who under-
went surgery after neoadjuvant hormonal treatment, and
only 33 months for those who had no surgery [18]. How-
ever, our study was not randomized; therefore its findings
should be assessed accordingly [18]. It is possible that pa-
tients with more advanced disease were not treated surgi-
cally [18]. Recommendations for hormonal treatment only
were based on the results of a randomized clinical trial
EORTC 10851 comparing tamoxifen alone with modified
radical mastectomy in patients aged 70 years or older [19].
The EORTC 10851 showed that hormonal treatment re-
sults in faster disease progression compared to surgical
treatment. However, there was no difference in the overall
survival between the two treatment groups in terms of
breast cancer [19]. Following the findings of the EORTC10851 study, breast surgery was performed only in 38%
patients with locally or regionally limited cancer who re-
ceived their first treatment at the IOL. Surgical treatment
was performed considerably less often than in other stud-
ies. According to the data of the Dutch Cancer Registry, as
many as 83% of patients aged 80 years or older with stage
I or stage II breast cancer underwent surgery in the
Netherlands in the period of 2001–2006 [14]. In the USA ,
surgery was performed in more than 98% of patients with
stage I or stage II disease between 1992 and 2003 [13].
A total of 36% of our patients were not treated in line
with the guidelines for the treatment of patients with
breast cancer. Van Leeuwen et al. found that patients
who underwent partial breast-conserving surgery with-
out radiation therapy had a higher rate of locoregional
recurrence than patients who were treated with surgery
plus radiation therapy [12]. They also observed longer
survival in breast cancer patients who underwent axillary
lymphadenectomy as compared to those who did not
undergo lymphadenectomy [12]. Contrary to their find-
ings, our results show that there was a higher mortality
among patients who received surgical treatment in line
with the guidelines and those who underwent lymphade-
nectomy than among patients not receiving surgical
treatment in line with the guidelines and those without
lymphadenectomy. Surgeons at the IOL therefore utilized
a more radical approach in patients with more advanced
and more aggressive cancer. This surgical approach is in
agreement with the modern concept of tailored treatment
for breast cancer patients [20].Conclusions
Relatively long life expectancy of breast cancer patients
aged 80 years or older presents us with new challenges.
Using multivariate statistical analysis, we found that the
pathological T-stage, pathological N-stage and estrogen
receptors are independent prognostic factors for the dur-
ation of breast cancer-specific survival of patients. In
this study, we found that our surgeons appropriately ad-
justed the extent of treatment according to the aggres-
siveness and extent of cancer and the biological age of
the patient.
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